Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824824 | 0.88 | TAAR1 (0.50) | TAAR1GPR52IDO1TSHRPLCG1 | |
| SCHEMBL11193295 | 0.86 | TAAR1 (0.48) | TAAR1GPR52IDO1TSHRPLCG1 | |
| SCHEMBL11912455 | 0.84 | TAAR1 (0.47) | TAAR1GPR52IDO1TSHRPLCG1 | |
| SCHEMBL28607303 | 0.84 | ADH1B (0.36) | TAAR1GPR52TSHRCYP2D6ALDH1A1 | |
| SCHEMBL27446055 | 0.78 | TAAR1 (0.54) | TAAR1GPR52IDO1TSHRCYP1A2 | |
| SCHEMBL5925354 | 0.78 | TAAR1 (0.54) | TAAR1GPR52IDO1TSHRCYP1A2 | |
| SCHEMBL29351396 | 0.78 | TAAR1 (0.71) | TAAR1GPR52IDO1TSHRCYP1A2 | |
| SCHEMBL6738136 | 0.78 | TAAR1 (0.71) | TAAR1GPR52IDO1TSHRCYP1A2 | |
| SCHEMBL33530596 | 0.78 | TAAR1 (0.58) | TAAR1GPR52IDO1TSHRPLCG1 | |
| SCHEMBL5604774 | 0.78 | TAAR1 (0.58) | TAAR1GPR52IDO1TSHRPLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015193910-A1 | ASYMMETRIC SYNTHESIS OF 2-SUBSTITUTED INDOLINES AND 3-SUBSTITUTED CINNOLINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-23 | — | — | WO | claimed |
| EP-3755732-A1 | KETONE-CONTAINING CONTROLLED RADICAL INITIATORS FOR POLYMERIZATION REACTIONS | 3M Innovative Properties Company (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2019162805-A1 | KETONE-CONTAINING CONTROLLED RADICAL INITIATORS FOR POLYMERIZATION REACTIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-08-29 | — | — | WO | disclosed |
| CN-106632130-B | Furodiazole compound and its application in preparation prevention and/or treatment diabetes B drug | 中国科学院海洋研究所 | 2019-07-26 | — | — | CN | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| CN-107973809-A | MACROCYCLES AS FACTOR XIA INHIBITORS | 百时美施贵宝公司 | 2018-05-01 | — | — | CN | disclosed |
| CN-105164113-B | Pyrroloamide inhibitors | 艾伯维公司 | 2018-03-02 | — | — | CN | disclosed |
| US-9901571-B2 | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| CN-102753555-B | Macrocycles as Factor XIA Inhibitors | 百时美施贵宝公司 | 2018-01-12 | — | — | CN | disclosed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1137415-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000033842-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5968960-A | ANTIISCHEMIC AGENTS AND HYPOTENSIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-19 | — | — | US | disclosed |
| US-5804590-A | ADMINISTERING DERIVATIVES OF THIAZOLIDINE; ANTI-DIABETIC AGENTS. | SANKYO COMPANY, LIMITED (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0783888-A1 | Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis | SANKYO COMPANY LIMITED (JP) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | TAAR1 149/4885GPR52 68/4885IDO1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.